Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №4 (2024) > The impact of atypical antipsychotics on the development of type 2 diabetes mellitus

The impact of atypical antipsychotics on the development of type 2 diabetes mellitus

Sabina E. Kurtmambetova , Yana V. Andrukh , Ruslan E. Kurtmambetov , Elena N. Primysheva , Irina N. Repinskaya

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Atypical antipsychotics (novell atypical generation antipsychotics) have entered clinical practice recently, but despite this, they have already managed to occupy one of the leading positions in modern therapy of mental disorders such as schizophrenia and bipolar affective disorder. It is known that treatment with antipsychotics of both generations is associated with a number of side effects. When using atypical antipsychotics, metabolic disorders, including carbohydrate metabolism, occupy a leading place. A number of scientific studies, the analysis of which we are conducting in this review, describe the mechanisms of development of such changes in glucose homeostasis as hyperglycemia and insulin resistance in patients receiving therapy with second-generation antipsychotics (atypical). Another proven side effect is an increase in appetite and an increase in body weight. It is obvious that such metabolic changes have the potential to lead to the development of type 2 diabetes mellitus in the long term. The relevance of the study lies in the fact that the use of atypical antipsychotics is not always among the causes of drug-induced diabetes mellitus. In this regard, not all internists, endocrinologists, general practitioners, and sometimes even psychiatrists consider patients receiving treatment with these drugs to be at increased risk. Consequently, primary and secondary prevention of diabetes mellitus among such patients may not be carried out or may be insufficient. In this review, through meta-analysis, we summarized data on the effect of the main representatives of atypical antipsychotics on the possibility of developing type 2 diabetes mellitus, and also examined in more depth the pathogenesis of carbohydrate metabolism disorders in patients receiving therapy with these drugs.
Keywords: atypical antipsychotics, diabetes mellitus, hyperglycemia, schizophrenia, bipolar affective disorder.

About the Author

Sabina E. Kurtmambetova 1 , Yana V. Andrukh 1 , Ruslan E. Kurtmambetov 1 , Elena N. Primysheva 1 , Irina N. Repinskaya 1

1 Vernadsky Crimean Federal University, Simferopol, Russia

References

1. Данилов Д.С. Современный взгляд на историю атипичных антипсихотических средств. Журнал неврологии и психиатрии им.
С.С. Корсакова. 2017;117(5):85-93.
Danilov D.S. A modern look at the history of atypical antipsychotics. Journal of Neurology and Psychiatry. S.S. Korsakov. 2017;117(5):85-93 (in Russian).
2. Сиволап Ю.П. Типичные и атипичные антипсихотики: насколько существенны различия? Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(11):125-9. DOI: 10.17116/jnevro 2018118111125. PMID: 30585617.
Sivolap Yu.P. Typical and atypical antipsychotics: how significant are the differences? Journal of Neurology and Psychiatry. S.S. Korsakov. 2018;118(11):125-9. DOI: 10.17116/jnevro2018118111125. PMID: 30585617 (in Russian).
3. Остроумова О.Д., Акимова Е.С., Кочетков А.И. Лекарственно-индуцированная гипергликемия. Клиническая фармакология и терапия. 2019;28(2):61-9. DOI: 10.32756/0869-5490-2019-2-61-69
Ostroumova O.D., Akimova E.S., Kochetkov A.I. Drug-induced hyperglycemia. Clinical pharmacology and therapy. 2019;28(2):61-9. DOI: 10.32756/0869-5490-2019-2-61-69 (in Russian).
4. Алешкина Г.А. Применение атипичных нейролептиков в лечении больных параноидной шизофренией, страдающих сахарным диабетом типа 2. Авторефер. дис. ... канд. мед. наук. М., 2010.
Aleshkina G.A. The use of atypical neuroleptics in the treatment of patients with paranoid schizophrenia and type 2 diabetes mellitus. Abstract. dis. ... cand. sci. (med.). Moscow, 2010 (in Russian).
5. Барденштейн Л.М., Мкртумян А.М., Алешкина Г.А. Состояние углеводного и липидного обмена у больных параноидной шизофренией при терапии атипичными антипсихотическими препаратами. Сахарный диабет. 2010;2.
Bardenshtein L.M., Mkrtumyan A.M., Aleshkina G.A. The state of carbohydrate and lipid metabolism in patients with paranoid schizophrenia during therapy with atypical antipsychotic drugs. Diabetes. 2010;2 (in Russian).
6. Højlund M, Lund LC, Andersen K et al. Association of Low-Dose Quetiapine and Diabetes. JAMA Netw Open 2021;4(5):e213209. DOI: 10.1001/jamanetworkopen.2021.3209. PMID: 33961038; PMCID: PMC8105749.
7. Istikoglou C, Mikirditsian O, Michelidakis C et al. Diabetes and atypical antipsychotics. Ann Gen Psychiatry 2008;7(Suppl.1):S105. DOI: 10.1186/1744-859X-7-S1-S105
8. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003;23(6):735-44. DOI: 10.1592/phco.23.6.735.32178. PMID: 12820816.
9. Rummel-Kluge C, Komossa K, Schwarz S et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123(2-3):225-33. DOI: 10.1016/j.schres.2010. 07.012. Epub 2010 Aug 7. PMID: 20692814; PMCID: PMC2957510.
10. Денисов Е.М. Метаболический синдром у больных шизофренией: роль антипсихотиков. Сообщение 1. Журнал психиатрии и медицинской психологии. 2010;1-2(24-25):151-60.
Denisov E.M. Metabolic syndrome in patients with schizophrenia: the role of antipsychotics. Post 1. Journal of Psychiatry and Medical Psychology. 2010;1-2(24-25):151-60 (in Russian).
11. Charlson F, van Ommeren M, Flaxman A et al. New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. Lancet 2019;394:240-8.
12. International Diabetes Federation. IDF Diabetes Atlas, 10th edn. Brussels, Belgium: 2021.
13. Горобец Л.Н., Литвинов А.В., Поляковская Т.П. Проблема соматического здоровья у психических больных: сахарный диабет 2. Социальная и клиническая психиатрия. 2013;23(4).
Gorobets L.N., Litvinov A.V., Polyakovskaya T.P. The problem of somatic health in mental patients: diabetes mellitus 2. Social and clinical psychiatry. 2013;23(4) (in Russian).
14. Горобец Л.Н. Нейроэндокринные дисфункции у больных шизофренией. Социальная и клиническая психиатрия. 2005;1:89-99.
Gorobets L.N. Neuroendocrine dysfunctions in patients with schizophrenia. Social and clinical psychiatry. 2005;1:89-99 (in Russian).
15. Liu Y, Li Z, Zhang M et al. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics 2013;6(Suppl.1):S17. DOI: 10.1186/1755-8794-6-S1-S17
16. Stubbs B, Vancampfort D, De Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015;132(2):144-57. DOI: 10.1111/acps.12439. Epub 2015 May 5. PMID: 25943829.
17. American Diabetes Association, American Psychiatric Association, APA, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Obes Res 2004;12:362-8. DOI: 10.1055/s-2004-815468. PMID: 14750042.
18. Lean ME, Pajonk FG. Patients on atypical antipsychotic drugs: another high-risk group for type 2 diabetes. Diabetes Care 2003;26(5):1597-605. DOI: 10.2337/diacare.26.5.1597. PMID: 12716824.
19. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13(1):27-35. DOI: 10.1038/sj.mp.4002066. Epub 2007 Sep 11. PMID: 17848919.
20. Schwenkreis P, Assion H-J. Atypical antipsychotics and diabetes mellitus. The world journal of biological psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry. 2004;5:73-82. DOI: 10.1080/15622970410029915

For citation:Kurtmambetova S.E., Andrukh Ya.V., Kurtmambetov R.E., Primysheva E.N., Repinskaya I.N. The impact of atypical antipsychotics on the development of type 2 diabetes mellitus. Clinical review for general practice. 2024; 5 (4): 9–14 (In Russ.). DOI: 10.47407/ kr2024.5.4.00414


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru